Goodwill impairment testing under ASC 350 carries real financial consequences — and with rising discount rates compressing fair values independent of operating performance, the margin for a poorly documented analysis has never been narrower.
Audience CFOs, Controllers, PE Sponsors, Buyers
Applies To Public Companies & Private Companies on Full GAAP
ASC 350 Goodwill Impairment DCF Reporting Units PE Exit
Goodwill impairment is an annual ASC 350 obligation, but interim testing is required whenever a triggering event occurs, not only at year-end.
Rising discount rates can push a reporting unit's fair value below carrying value on their own, independent of operating performance.
A defensible file pairs a board-reconciled forecast and sourced WACC with quarterly triggering-event memos and a sensitivity matrix.
For PE-backed companies, a poorly supported charge creates friction in a sell-side process; a well-documented one is a manageable disclosure.
We acquired a company. Why are we stuck testing goodwill every year?
Goodwill is the premium you paid above the fair value of the identifiable net assets you acquired: workforce, customer relationships, brand, strategic position. None of it shows up as a discrete line item, so U.S. GAAP makes public companies test it for impairment annually, or sooner if something triggers it, rather than amortize it.
The test asks one question: does the fair value of the reporting unit holding the goodwill still exceed its carrying value? If not, you book the difference as a non-cash write-down through the income statement. And it does not reverse. For how the purchase price allocation sets the goodwill balance in the first place, see our article on Purchase Price Allocations Under ASC 805.
We are private and PE-backed. Do the same rules apply to us?
Maybe not. Private companies can elect the goodwill amortization alternative under ASU 2014-02, which lets you amortize goodwill straight-line over up to 10 years and swaps the annual test for a trigger-only model. Because the balance is shrinking, your impairment exposure at any trigger date is lower, though not zero.
One wrinkle: if you also elect the intangibles alternative (ASU 2014-18), more intangibles fold into goodwill and your starting balance is larger. We cover the trade-offs in The PCC Election for Private Company Acquisitions. Step one is simply confirming which framework your entity is on. Everything below assumes full GAAP.
You can start with a qualitative "Step Zero": is it more likely than not that fair value still beats carrying value? If yes, you are done. If not, or if you skip it, you run the quantitative test. That compares the reporting unit's fair value, usually a discounted cash flow analysis backed up by comparable company or precedent transaction multiples, against its carrying value.
Carrying value higher than fair value? The gap is your impairment charge, capped at the goodwill allocated to that unit. One detail that trips people up: you test at the reporting unit level, not the consolidated company, and goodwill has to be allocated to those units in a documented, supportable way.
That is the trap. Annual testing is the floor, not the schedule. ASC 350-20-35-3C requires interim testing whenever a triggering event makes impairment more likely than not, and you have to evaluate for triggers at every reporting date. Common ones: a sustained drop in market cap below book, the loss of a major customer or key personnel, deteriorating competition or cost structure, and, very much in play right now, a jump in your discount rate that compresses fair value on its own.
Key Reporting Reminder Document a triggering-event memo every quarter and build it into your close, not your year-end scramble. The SEC and PCAOB keep flagging weak interim assessments, and the cost of a restatement or material weakness dwarfs the cost of a quarterly memo.
What does a file we can actually defend contain?
Five things: your WACC derivation with sourced inputs; a long-term forecast reconciled to the board-approved plan; a bridge explaining any year-over-year change in key assumptions; a sensitivity matrix as a standard exhibit, not an afterthought; and those quarterly trigger memos, retained with the annual file.
One more: if you hire an outside valuation specialist, "we relied on the valuation firm" will not satisfy your auditor. They will ask whether management challenged the growth rates, the discount rate, and the comp selection. You and your controller need to understand the model well enough to defend it.
Carrying forward last year's discount rate while updating projections. In a rising-rate environment, that is a material error.
Leaning on the qualitative step as an escape hatch. It is a real tool, but auditors are skeptical when a thin-margin or declining unit "qualitatively" shows no impairment.
Defining reporting units differently from how the business is run. That mismatch surfaces fast in an audit or SEC review.
Letting the model lag reality. If last year's projections did not materialize, this year's analysis has to say so and reset to what the business has actually proven it can do.
We are heading toward an exit. Does an impairment hurt us?
Not automatically, but it creates a story you have to manage. A buyer's quality of earnings team will dig into what triggered the charge, whether things have improved since, and whether the goodwill still on the books is supportable. If the charge came from a discrete, since-resolved event (a lost customer, a killed product line), you can present it as closed. If it reflects broader erosion in the unit's economics, expect hard questions about whether today's assumptions hold.
Practical takeaway: test with the same rigor in year three of the hold as in year one. A well-documented charge with a clear trigger, a defensible model, and real sensitivity analysis is a manageable disclosure. One that looks reactive or inconsistent with what you told the board and lenders creates friction that hits both timeline and price. Note too that the QofE advisor will normalize the charge as non-cash and non-recurring for adjusted earnings, but separately test whether the remaining goodwill is supportable. Two different analyses. Your file should survive both.
Goodwill impairment testing is an annual obligation with real teeth. With rising discount rates pushing fair values down regardless of how the business is performing, the margin for error has narrowed. The goal is not to engineer a DCF that dodges a charge. It is to build a process you can defend to your auditor, your board, your sponsor, and the buyer across the table at exit. A well-documented charge is manageable. One that surfaces through audit challenge or diligence is not.
Related Article For how the purchase price allocation determines the goodwill balance that later gets tested, see: Purchase Price Allocations Under ASC 805.
Goodwill Impairment Testing and Valuation Advisory
The McLean Group's Valuation Advisory team performs goodwill impairment testing for PE-backed portfolio companies and privately held businesses across every sector. Whether you need a full quantitative analysis, a supportable qualitative assessment, or a triggering-event framework wired into your quarterly close, we deliver audit-ready work on middle-market timelines.
